Andrew Luber

Andrew Luber Email and Phone Number

President & CEO at Virion Therapeutics, LLC @ Virion Therapeutics
Andrew Luber's Location
Greater Philadelphia, United States, United States
Andrew Luber's Contact Details
About Andrew Luber

• Infectious diseases trained clinical pharmacist with greater than 25 years experience in antiviral and infectious diseases research• Early stage clinical and translational medicine drug development experience across a wide range of therapeutic indications with emphasis on antiviral therapiesHighlights include:- Investigator in more than 40 Phase I-III multicenter clinical trials (including 5 Phase Ia/b First in Human Trials) and 25 investigator initiated research studies .- Authored textbook chapters and numerous articles in peer-reviewed journals and on-line resources in the area of HIV Pharmacology and Pharmacokinetics.- Helped to develop the American Academy of HIV Medicine’s Self-Directed Study Guide by authoring the Pharmacology and Pharmacokinetic sections. - Task force and core faculty member that helped to develop accreditation programs and standards for mid-level HCV practitioners for the American Association for Study of Liver Disease (AASLD). Specialties: Clinical Pharmacology, Clinical Research, Antivirals, Infectious Diseases, Technical and Scientific Due Diligence

Andrew Luber's Current Company Details
Virion Therapeutics

Virion Therapeutics

View
President & CEO at Virion Therapeutics, LLC
Andrew Luber Work Experience Details
  • Virion Therapeutics
    President & Ceo
    Virion Therapeutics Oct 2020 - Present
    Virion Therapeutics, LLC, is a science-driven company whose mission is to cure cancer and chronic infectious diseases through the development of novel and accessible CD8+ T cell-based immunotherapies. Our proprietary technologies combine genetically encoded checkpoint modifiers, with selected and optimized target-specific antigens, that are delivered within a highly immunogenic and adaptable viral vector platform which promote potent, prolonged, and broad CD8+ T cell responses. Virion was founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with specific expertise in vaccine, cancer and infectious disease research. Combined with this foundation, Virion has developed a best-in-class, experienced biotechnology management team which is augmented by a global advisory board with extensive preclinical and clinical expertise in antiviral, vaccine, and immuno-oncology. Our lead VRON-0200 program for treatment of Chronic Hepatitis B Virus is scheduled for the clinic at the end of 2022.www.VirionTx.com
  • Virion Therapeutics
    President & Coo
    Virion Therapeutics Jan 2018 - Sep 2020
    Virion Therapeutics, LLC, is a science-driven company whose mission is to cure cancer and chronic infectious diseases through the development of novel and accessible CD8+ T cell-based immunotherapies. Our proprietary technologies combine genetically encoded checkpoint modifiers, with selected and optimized target-specific antigens, that are delivered within a highly immunogenic and adaptable viral vector platform which promote potent, prolonged, and broad CD8+ T cell responses. Virion was founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with specific expertise in vaccine, cancer and infectious disease research. Combined with this foundation, Virion has developed a best-in-class, experienced biotechnology management team which is augmented by a global advisory board with extensive preclinical and clinical expertise in antiviral, vaccine, and immuno-oncology. Our lead VRON-0200 program for treatment of Chronic Hepatitis B Virus is scheduled for the clinic at the end of 2022.www.VirionTx.com
  • Moerae Matrix, Inc.
    Vp Clinical Pharmacology
    Moerae Matrix, Inc. Mar 2014 - Oct 2019
    Moerae Matrix develops innovative therapies for patients suffering from inflammatory and fibrotic disorders via a pipeline of novel first-in-class peptide based MAPKAP Kinase 2 (MK2) inhibitors. Key roles included helping to advance the lead candidate (MMI-0100) into the clinic and through 3 Phase 1 clinical trials for treatment of Idiopathic Pulmonary Fibrosis as well as continued advancement of the pipeline peptides through preclinical development.
  • Medical Consultant/Private Practice
    Clinical Pharmacist/Pharmacologist
    Medical Consultant/Private Practice Apr 2003 - Feb 2014
    Clinical consultant to various pharmaceutical companies, advertising agencies, vendors and medical education groups in the areas of antiviral drug development, medical education and on-label promotional pieces. In addition, performed numerous investigator initiated research studies in the areas of HIV/HCV as a Consultant to Garden State Infectious Diseases in Voorhees NJ.
  • Tower Id Research (4/2001-4/2003) And Pacific Oaks Research (12/99-2/2001)
    Executive Director Of Research; Clinical Pharmacy Specialist
    Tower Id Research (4/2001-4/2003) And Pacific Oaks Research (12/99-2/2001) Dec 1999 - Apr 2003
    - Responsible for the procurement, contract/study budget, and oversight of more than 40 Phase I-III clinical trials, including 4 Ia first in human studies.- Development, procurement, implementation, evaluation and presentation/publication of 15 investigator initiated Phase IV studies. - Management and oversight of day-to-day functions of large private practice research centers, including staffing, budgetary and regulatory issues.

Andrew Luber Skills

Infectious Diseases Clinical Trials Drug Development Pharmacology Clinical Research Medical Writing Clinical Pharmacology Pharmaceutical Industry Pharmacokinetics Medical Education Medical Affairs Clinical Development Lifesciences Fda Life Sciences Vaccines Ind Pharmacovigilance Clinical Pharmacy Internal Medicine Immunology Pharmacy Gcp Virology Cme Due Diligence Clinical Strategy Hiv/aids Hepatitis

Andrew Luber Education Details

  • University Of California, San Francisco
    University Of California, San Francisco
    Infectious Diseases Pharmacotherapy Fellowship
  • University Of California, San Francisco
    University Of California, San Francisco
    Residency In Infectious Diseases
  • University Of California, San Francisco
    University Of California, San Francisco
    Residency
  • Temple University
    Temple University
    Pharmd
  • Temple University
    Temple University
    Bs. Pharm.

Frequently Asked Questions about Andrew Luber

What company does Andrew Luber work for?

Andrew Luber works for Virion Therapeutics

What is Andrew Luber's role at the current company?

Andrew Luber's current role is President & CEO at Virion Therapeutics, LLC.

What is Andrew Luber's email address?

Andrew Luber's email address is a.****@****ink.net

What is Andrew Luber's direct phone number?

Andrew Luber's direct phone number is +151059*****

What schools did Andrew Luber attend?

Andrew Luber attended University Of California, San Francisco, University Of California, San Francisco, University Of California, San Francisco, Temple University, Temple University.

What skills is Andrew Luber known for?

Andrew Luber has skills like Infectious Diseases, Clinical Trials, Drug Development, Pharmacology, Clinical Research, Medical Writing, Clinical Pharmacology, Pharmaceutical Industry, Pharmacokinetics, Medical Education, Medical Affairs, Clinical Development.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.